Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Olaparib in Breast cancer recurrent: NCT05700669 Clinical Landscape Report 2026
16 October 2026
NCT05700669 clinical landscape for Breast cancer recurrent: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Temozolomide in Recurrent Glioblastoma: NCT05700955 Clinical Landscape Report 2026
16 October 2026
NCT05700955 clinical landscape for Recurrent Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Bevacizumab in Recurrent Glioblastoma: NCT05718466 Clinical Landscape Report 2026
16 October 2026
NCT05718466 clinical landscape for Recurrent Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ITI-1001 in Glioblastoma Multiforme: NCT05698199 Clinical Landscape Report 2026
16 October 2026
NCT05698199 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
PRO-1160 in Mantle-Cell Lymphoma: NCT05721222 Clinical Landscape Report 2026
16 October 2026
NCT05721222 clinical landscape for Mantle-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CA9hu-1 in Mesothelioma, Malignant: NCT05698238 Clinical Landscape Report 2026
16 October 2026
NCT05698238 clinical landscape for Mesothelioma, Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fosifloxuridine nafalbenamide in Microsatellite instability-high colorectal cancer: NCT05714553 Clinical Landscape Report 2026
16 October 2026
NCT05714553 clinical landscape for Microsatellite instability-high colorectal cancer: endpoints, sponsor, phase, geography, readouts, asset context and devel…
![[68Ga]Ga-DPI-4452 in Pancreatic Ductal Adenocarcinoma: NCT05706129 Clinical Landscape Report 2026](https://synapse-static.patsnap.com/strapi-static/Blog_cover_03_d2c7dad0d6.jpg)
9 min read
[68Ga]Ga-DPI-4452 in Pancreatic Ductal Adenocarcinoma: NCT05706129 Clinical Landscape Report 2026
16 October 2026
NCT05706129 clinical landscape for Pancreatic Ductal Adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
D2C7-based immunotoxins(Istari Oncology, Inc.) in Glioblastoma Multiforme: NCT05734560 Clinical Landscape Report 2026
16 October 2026
NCT05734560 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Imatinib mesylate in Triple Negative Breast Cancer: NCT05722795 Clinical Landscape Report 2026
16 October 2026
NCT05722795 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
68Ga-NY104 in Renal Cell Carcinoma: NCT05728515 Clinical Landscape Report 2026
16 October 2026
NCT05728515 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab in Metastatic breast cancer: NCT05741164 Clinical Landscape Report 2026
16 October 2026
NCT05741164 clinical landscape for Metastatic breast cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.